account_id none on file
legal_name Fortress Biotech, Inc.
ticker FBIO
cik 1429260
domain fortressbiotech.com
linkedin_company_url https://www.linkedin.com/company/fortress-biotech/
entry_point_account_id none on file
name Fortress Biotech Inc.
exchange Nasdaq
sector Health Care
hq Bay Harbor Islands, FL, United States
sector index/company/sector/health-care/
calls 0 filings 22 executives 3 family 0
why_nownone on file
callsnone on file
filings
In connection with the termination, Avenue repurchased shares previously issued to AnnJi for nominal consideration and paid $ 0.2 million for legal expense reimbursement, which was accounted for as consideration payable to a customer and reduced revenue recognized.
filing / Aug 13, 2026 / receipt
As of June 30, 2026 and December 31, 2025, the Company had $ 1.2 million of restricted cash representing pledges to secure letters of credit in connection with certain office leases.
filing / Aug 13, 2026 / receipt
The Desk Share Agreement between the Company and TGTX, as amended, required TGTX to pay 65 % of the average annual rent for the Company’s New York, NY office space.
filing / Aug 13, 2026 / receipt
The increase of $2.7 million, or 26%, at Fortress is due to increased personnel and severance expenses of $2.1 million, Cyprium’s increased personnel-related expenses of $3.0 million and increased legal expense of $0.5 million, partially offset by decreased stock-based compensation at Fortress of $2.6 million related to fully vested LTIP grants in 2025, and decreased legal costs associated with the Checkpoint transac
filing / Aug 13, 2026 / receipt
A primary trend in the healthcare industry in the United States and elsewhere is cost containment. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirement
filing / Aug 13, 2026 / receipt
The implementation of any of the cost containment measures or other healthcare reforms discussed above may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Aug 13, 2026 / receipt
In connection with the termination, Avenue repurchased shares previously issued to AnnJi for nominal consideration and paid $ 0.2 million for legal expense reimbursement, which was accounted for as consideration payable to a customer and reduced revenue recognized.
filing / Aug 13, 2026 / receipt
As of June 30, 2026 and December 31, 2025, the Company had $ 1.2 million of restricted cash representing pledges to secure letters of credit in connection with certain office leases.
filing / Aug 13, 2026 / receipt
The Desk Share Agreement between the Company and TGTX, as amended, required TGTX to pay 65 % of the average annual rent for the Company’s New York, NY office space.
filing / Aug 13, 2026 / receipt
The increase of $2.7 million, or 26%, at Fortress is due to increased personnel and severance expenses of $2.1 million, Cyprium’s increased personnel-related expenses of $3.0 million and increased legal expense of $0.5 million, partially offset by decreased stock-based compensation at Fortress of $2.6 million related to fully vested LTIP grants in 2025, and decreased legal costs associated with the Checkpoint transac
filing / Aug 13, 2026 / receipt
A primary trend in the healthcare industry in the United States and elsewhere is cost containment. The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system, including implementing cost-containment programs to limit the growth of government-paid healthcare costs, including price controls, restrictions on reimbursement and requirement
filing / Aug 13, 2026 / receipt
The implementation of any of the cost containment measures or other healthcare reforms discussed above may prevent us from being able to generate revenue, attain profitability or commercialize our products.
filing / Aug 13, 2026 / receipt
executives
| David Jin | Chief Financial Officer | receipt | |
| Malcolm Hoenlein | director | - | receipt |
| Robyn Hunter | Chief Financial Officer | - | receipt |
familynone on file
upcoming
| 2026-11-13 | earnings call | scheduled | ir |
changes
| 2022-07-22 | Vice President, appointed | sec_8k |
| 2017-06-30 | Chief Financial Officer, appointed | sec_8k |
| 2014-02-26 | director, appointed | sec_8k |
mcp_package_hint
slug fortress-biotech-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$